Wall Street Analysts Reiterated Ratings of These Shares in the Healthcare Sector

Wall St. Watchdog reveals information about companies for which stock analysts reiterated ratings in the Healthcare sector for the week ending October 28th, 2011

  • Human Genome (NASDAQ:HGSI): Stifel Nicolaus reiterated its rating of Buy for this company and changed its price target from $26 to $20. About the company: Human Genome Sciences, Inc. researches and develops proprietary pharmaceutical and diagnostic products. The Company’s products predict, prevent, detect, treat, and cure disease based on the discovery of human and microbial genes.
  • Questcor Pharma (NASDAQ:QCOR): Oppenheimer reiterated its rating of Outperform for this company and changed its price target from $35 to $45. About the company: Questcor Pharmaceuticals, Inc. develops and commercializes novel central nervous system-focused therapeutics that address significant unmet medical needs. The Company’s primary product is a natural source adrenocorticotropic hormone indicated for the treatment of acute exacerbations of multiple sclerosis, as well as a number of other conditions.
  • Celgene (NASDAQ:CELG): Summer Street Research reiterated its rating of Buy for this company and changed its price target from $71 to $89. UBS reiterated its rating of Buy for this company and changed its price target from $71 to $75. About the company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Vertex Pharm (NASDAQ:VRTX): UBS reiterated its rating of Neutral for this company and changed its price target from $56 to $47. About the company: Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.
  • Bristol-Myers (NYSE:BMY): UBS reiterated its rating of Neutral for this company and changed its price target from $30 to $32. About the company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Zimmer Hldgs (NYSE:ZMH): Wunderlich reiterated its rating of Hold for this company and changed its price target from $65 to $60. About the company: Zimmer Holdings, Inc. designs, develops, manufactures, and markets orthopaedic and dental reconstructive implants, spinal implants, trauma products and related surgical products. The Company also provides other healthcare related services. Zimmer markets its products in the United States and other countries around the world.

(Note: Selected financial data are sourced from Briefing.com via the Wall St. Journal. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>